NCT02890069 - A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Biotech Hunter

Enrollment

298

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Interventions

BIOLOGICAL

PDR001

anti-PD1 antibody

DRUG

LCL161

DRUG

Everolimus

DRUG

Panobinostat

DRUG

QBM076

DRUG

HDM201

Trial Locations (25)

10002

Novartis Investigative Site, Taipei

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

28041

Novartis Investigative Site, Madrid

31008

Novartis Investigative Site, Pamplona

48109

The Regents of the University of Michigan, Ann Arbor

63110

Washington University Medical School SC, St Louis

77030

University of Texas MD Anderson Cancer Center, Houston

78229

UT Health San Antonio Mays Cancer Center, San Antonio

84112

Huntsman Cancer Institute, Salt Lake City

89081

Novartis Investigative Site, Ulm

90404

UCLA Santa Monica Hematology / Oncology SC, Santa Monica

97080

Novartis Investigative Site, Würzburg

98105

Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital, Boston

07740

Novartis Investigative Site, Jena

1066 CX

Novartis Investigative Site, Amsterdam

2300 RC

Novartis Investigative Site, Leiden

3075 EA

Novartis Investigative Site, Rotterdam

3584CX

Novartis Investigative Site, Utrecht

05505

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

SM2 5PT

Novartis Investigative Site, Sutton

M20 4BX

Novartis Investigative Site, Manchester

OX3 7LJ

Novartis Investigative Site, Oxford